G
Giulia Parisi
Researcher at University of California, Los Angeles
Publications - 33
Citations - 3390
Giulia Parisi is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Immunotherapy & DNA methylation. The author has an hindex of 16, co-authored 33 publications receiving 2360 citations.
Papers
More filters
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Elisabetta Fratta,Sandra Coral,Alessia Covre,Giulia Parisi,Francesca Colizzi,Riccardo Danielli,Hugues J. M. Nicolay,Luca Sigalotti,Michele Maio +8 more
TL;DR: The pharmacologic modulation of CTA expression profiles on neoplastic cells by DNA hypomethylating drugs will be discussed as a feasible approach to design new combination therapies potentially able to improve the clinical efficacy of currently adopted CTA‐based immunotherapeutic regimens in cancer patients.
Journal ArticleDOI
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.
Jonathan T. Sockolosky,Eleonora Trotta,Giulia Parisi,Lora Picton,Leon Su,Alan C. Le,Akanksha Chhabra,Stephanie L. Silveria,Benson M. George,Indigo Chris King,Matthew Tiffany,Kevin Jude,Leah V. Sibener,David Baker,Judith A. Shizuru,Antoni Ribas,Jeffrey A. Bluestone,K. Christopher Garcia +17 more
TL;DR: Treatment of mice with IL-2 improved the ability of engineered T cells to reject tumors with no obvious side effects, and this type of approach may provide a way to mitigate toxicities associated with some cytokine-based immunotherapies.
Journal ArticleDOI
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Blanca Homet Moreno,Jesse M. Zaretsky,Angel Garcia-Diaz,Jennifer Tsoi,Giulia Parisi,Lidia Robert,Katrina Meeth,Abibatou Ndoye,Marcus Bosenberg,Ashani T. Weeraratna,Thomas G. Graeber,Begoña Comin-Anduix,Siwen Hu-Lieskovan,Antoni Ribas +13 more
TL;DR: Response to PD-1 blockade therapy in tumor models requires CD4 and CD8 T cells and costimulation that is mediated by dendritic cells and macrophages, and exhibited a more inflammatory profile by RNA sequencing analysis.